Siegfried Holding AG is a leading global contract development and manufacturing organisation (CDMO) specialising in the production of active pharmaceutical ingredients (APIs) and finished dosage forms.

Founded in 1872 and headquartered in Zofingen, Switzerland, Siegfried boasts over 150 years of pharmaceutical and chemical expertise. The company operates a global network of 13 production sites across three continents, providing integrated services to the pharmaceutical industry. Siegfried's comprehensive offerings encompass the entire drug lifecycle, from chemical and analytical development to pilot and commercial-scale manufacturing.

Key Products and Services:

• Drug Prroducts:
  • Exclusive Synthesis: Custom manufacturing of APIs tailored to clients' specific requirements.
  • API Portfolio: A broad range of generic APIs available for various therapeutic areas.
  • Viral Vectors: Production of viral vectors through its subsidiary, DINAMIQS.
• Drug Products:
  • Oral Solids: Development and manufacturing of tablets and capsules.
  • Steriles: Production of sterile injectable products, including vials and ampoules.
  • Ophthalmics: Manufacturing of eye care products.
  • Inhalation Products: Development and production of inhalable medications.
• Technologies:
  • Advanced technological capabilities to support complex drug development and manufacturing processes.

Siegfried is committed to sustainability and innovation, continuously investing in state-of-the-art facilities and technologies to meet the evolving needs of the pharmaceutical industry. With a workforce of approximately 3,797 employees, the company maintains a strong presence in key markets, including the US, Europe, and Asia.

By combining its extensive experience with a global footprint, Siegfried serves as a reliable partner for pharmaceutical companies, delivering high-quality products and services that contribute to the advancement of global health.